Clinical Trial: Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis

U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07636655) titled 'Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis' on June 04.

Brief Summary: ANCA-associated vasculitis is a serious autoimmune disease. The standard treatment is rituximab (RTX), which depletes B-cells to control inflammation. However, identifying patients at high risk of relapse remains a challenge, often leading to unnecessarily long treatments and side effects. Recent research suggests that RTX also impacts CD8+ T-cells, which could serve as valuable markers for better disease monitoring.

The main goal of the NALVANCA cohort is to identify biomarkers within these CD8+ T-cells. Researchers aim to find b...